GRAP2 and neoplasm: Furthermore, the NSCLC cases with mutation in FAT1 demonstrated lower levels of the following gene clusters than those in cases with wild-type FAT1: immune checkpoint (CTLA-4, Figure 3A); tumor immune microenvironment (IL6, Figure 3A); T-cell effector and IFN-γ-associated signatures (EOMES, GZMA, GZMB, IRF1, and TBX21; Figure 5A); and T-cell receptor (TCR)-related genes (CD3G, CD3D, CD4, CD8A, CD74, GRAP2, IKZF3, LCK, and TIGIT; Figure 5B).